Liver toxicity of initial antiretroviral drug regimens including two nucleoside analogs plus one non-nucleoside analog or one ritonavir-boosted protease inhibitor in hiv/hcv-coinfected patients
HIV Clinical Trials, 04/23/2012Macías J et al.
Regimens including EFV, NVP, or PI/r are generally safe in treatment–naïve HIV/HCV–coinfected patients. Grade 3–4 TE are less commonly seen with EFV than with PI/r. Discontinuations due to hepatotoxicity were less frequent for patients receiving EFV than for those treated with NVP.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.